Literature DB >> 23392352

Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera?

Maurizio Zangari1, Louis Fink, Giulia Tolomelli, Jasmine C H Lee, Brady L Stein, Kimberly Hickman, Sabina Swierczek, Todd W Kelley, Tamara Berno, Alison R Moliterno, Jerry L Spivak, Victor R Gordeuk, Josef T Prchal.   

Abstract

Thromboses represent a major cause of morbidity and mortality in polycythemia vera but the contributing mechanisms are not fully described. To evaluate whether environmental conditions such as altitude/hypoxia could impact thrombosis history, we retrospectively analyzed thrombosis history in 71 polycythemia vera patients living at an elevation of 5000 feet or more in the Salt Lake City (SLC) area and 166 polycythemia vera patients living near sea level in the Baltimore (BLM) area. The SLC cohort was older with a longer disease duration. No significant differences in type of anticoagulation therapy or prothrombotic factors were present between the two cohorts. After adjusting for age, sex and disease duration, SLC patients experienced an estimated 3.9-fold increase in the odds of a history of thrombosis compared with BLM patients (95% confidence interval 1.8-7.6; P=0.0004). A history of a cardiovascular event was present in 58% of the SLC patients compared with 27% of the BLM patients (P<0.0001). Before diagnosis, thrombosis occurred in 18 and 4% of the SLC and BLM groups, respectively (P=0.003). No correlation between the JAK2 allele burden and thrombosis was observed in this study. This retrospective study suggests that even moderate hypoxia associated with 5000 feet elevation should be considered as an independent prothrombotic risk factor. This observation needs to be confirmed by prospective studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23392352      PMCID: PMC3796441          DOI: 10.1097/MBC.0b013e32835bfdb9

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  31 in total

Review 1.  Polycythemia vera: myths, mechanisms, and management.

Authors:  Jerry L Spivak
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

2.  Two routes to functional adaptation: Tibetan and Andean high-altitude natives.

Authors:  Cynthia M Beall
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-09       Impact factor: 11.205

3.  Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.

Authors:  Eric Lippert; François Girodon; Emma Hammond; Jaroslav Jelinek; N Scott Reading; Boris Fehse; Katy Hanlon; Mirjam Hermans; Céline Richard; Sabina Swierczek; Valérie Ugo; Serge Carillo; Véronique Harrivel; Christophe Marzac; Daniela Pietra; Marta Sobas; Morgane Mounier; Marina Migeon; Sian Ellard; Nicolaus Kröger; Richard Herrmann; Josef T Prchal; Radek C Skoda; Sylvie Hermouet
Journal:  Haematologica       Date:  2008-11-10       Impact factor: 9.941

4.  Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia.

Authors:  Sonny O Ang; Hua Chen; Kiichi Hirota; Victor R Gordeuk; Jaroslav Jelinek; Yongli Guan; Enli Liu; Adelina I Sergueeva; Galina Y Miasnikova; David Mole; Patrick H Maxwell; David W Stockton; Gregg L Semenza; Josef T Prchal
Journal:  Nat Genet       Date:  2002-11-04       Impact factor: 38.330

5.  "Living high-training low": effect of moderate-altitude acclimatization with low-altitude training on performance.

Authors:  B D Levine; J Stray-Gundersen
Journal:  J Appl Physiol (1985)       Date:  1997-07

6.  Low-dose aspirin in polycythaemia vera: a pilot study. Gruppo Italiano Studio Policitemia (GISP).

Authors: 
Journal:  Br J Haematol       Date:  1997-05       Impact factor: 6.998

7.  Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989.

Authors:  B J Anía; V J Suman; J L Sobell; M B Codd; M N Silverstein; L J Melton
Journal:  Am J Hematol       Date:  1994-10       Impact factor: 10.047

8.  Efficacy and safety of low-dose aspirin in polycythemia vera.

Authors:  Raffaele Landolfi; Roberto Marchioli; Jack Kutti; Heinz Gisslinger; Gianni Tognoni; Carlo Patrono; Tiziano Barbui
Journal:  N Engl J Med       Date:  2004-01-08       Impact factor: 91.245

9.  Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.

Authors:  P D Berk; J D Goldberg; P B Donovan; S M Fruchtman; N I Berlin; L R Wasserman
Journal:  Semin Hematol       Date:  1986-04       Impact factor: 3.851

10.  JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.

Authors:  Alessandra Carobbio; Guido Finazzi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro M Vannucchi; Chiara M Dellacasa; Silvia Salmoiraghi; Federica Delaini; Alessandro Rambaldi; Tiziano Barbui
Journal:  Exp Hematol       Date:  2009-06-24       Impact factor: 3.084

View more
  6 in total

1.  Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia.

Authors:  Neha Gupta; Anita Sahu; Amit Prabhakar; Tathagata Chatterjee; Tarun Tyagi; Babita Kumari; Nilofar Khan; Velu Nair; Nitin Bajaj; Manish Sharma; Mohammad Zahid Ashraf
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-18       Impact factor: 11.205

Review 2.  D-dimer as an indicator of prognosis in SARS-CoV-2 infection: a systematic review.

Authors:  Sofia Vidali; Daniele Morosetti; Elsa Cossu; Maria Luisa Eliana Luisi; Silvia Pancani; Vittorio Semeraro; Guglielmo Consales
Journal:  ERJ Open Res       Date:  2020-07-13

3.  Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia.

Authors:  Radhika Gangaraju; Jihyun Song; Soo Jin Kim; Tsewang Tashi; Brandi N Reeves; Krishna M Sundar; Perumal Thiagarajan; Josef T Prchal
Journal:  Blood Adv       Date:  2020-03-24

4.  Hypoxia downregulates protein S expression.

Authors:  Vijaya S Pilli; Arani Datta; Sadaf Afreen; Donna Catalano; Gyongyi Szabo; Rinku Majumder
Journal:  Blood       Date:  2018-05-21       Impact factor: 25.476

5.  Chronic high-altitude exposure and the epidemiology of ischaemic stroke: a systematic review.

Authors:  Esteban Ortiz-Prado; Simone Pierina Cordovez; Eduardo Vasconez; Ginés Viscor; Paul Roderick
Journal:  BMJ Open       Date:  2022-04-29       Impact factor: 3.006

Review 6.  Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis.

Authors:  Victor R Gordeuk; Nigel S Key; Josef T Prchal
Journal:  Haematologica       Date:  2019-03-14       Impact factor: 9.941

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.